CD274 and non-small cell lung carcinoma: Indeed, in the phase II trial CITYSCAPE, 135 patients affected by advanced NSCLC with PD-L1 expression ≥1% were randomized (1:1) to receive atezolizumab (anti-PD-L1) plus tiragolumab or atezolizumab alone.